These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 29222268

  • 1. Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?
    Davies A.
    Hematology Am Soc Hematol Educ Program; 2017 Dec 08; 2017(1):284-294. PubMed ID: 29222268
    [Abstract] [Full Text] [Related]

  • 2. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.
    McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM.
    Haematologica; 2018 Nov 08; 103(11):1899-1907. PubMed ID: 29903764
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB.
    J Clin Oncol; 2012 Oct 01; 30(28):3460-7. PubMed ID: 22665537
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N, Uner A, Benekli M, Barista I.
    Cancer; 2012 Sep 01; 118(17):4173-83. PubMed ID: 22213394
    [Abstract] [Full Text] [Related]

  • 5. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
    Xia Y, Zhang X.
    Acta Haematol; 2020 Sep 01; 143(6):520-528. PubMed ID: 32074595
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ, Gang AO, Brown P, Pedersen M, Knudsen H, Nielsen SL, Poulsen T, Wirenfeldt Klausen T, Høgdall E, Nørgaard P.
    PLoS One; 2017 Sep 01; 12(10):e0186983. PubMed ID: 29088292
    [Abstract] [Full Text] [Related]

  • 8. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, Visco C, Montes-Moreno S, Zhang L, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, Medeiros LJ, Hu S, Young KH.
    Oncotarget; 2016 Jan 19; 7(3):2401-16. PubMed ID: 26573234
    [Abstract] [Full Text] [Related]

  • 9. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H.
    J Clin Oncol; 2014 Dec 10; 32(35):3996-4003. PubMed ID: 25385729
    [Abstract] [Full Text] [Related]

  • 10. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G, German High-Grade Lymphoma Study Group.
    J Clin Oncol; 2017 Aug 01; 35(22):2515-2526. PubMed ID: 28525305
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Double-Hit Large B Cell Lymphoma.
    Khelfa Y, Lebowicz Y, Jamil MO.
    Curr Oncol Rep; 2017 Sep 26; 19(11):74. PubMed ID: 28952038
    [Abstract] [Full Text] [Related]

  • 13. Optimizing initial therapy in DLBCL.
    Thieblemont C, Bernard S, Meignan M, Molina T.
    Best Pract Res Clin Haematol; 2018 Sep 26; 31(3):199-208. PubMed ID: 30213389
    [Abstract] [Full Text] [Related]

  • 14. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD.
    J Clin Oncol; 2012 Oct 01; 30(28):3452-9. PubMed ID: 22851565
    [Abstract] [Full Text] [Related]

  • 15. New high-risk molecular subtypes of DLBCL identified.
    Killock D.
    Nat Rev Clin Oncol; 2019 Feb 01; 16(2):68. PubMed ID: 30560951
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
    Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D.
    J Clin Oncol; 2019 Dec 10; 37(35):3359-3368. PubMed ID: 31498031
    [Abstract] [Full Text] [Related]

  • 17. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP, Mihaljevic B, Jakovic L, Martinovic VC, Fekete MD, Andjelic B, Antic D, Bogdanovic A, Boricic N, Terzic T, Jelicic J, Milenkovic S.
    J BUON; 2015 Dec 10; 20(3):820-8. PubMed ID: 26214636
    [Abstract] [Full Text] [Related]

  • 18. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
    Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Siebert R, Loeffler M, Rosenwald A, Ott G, German High-Grade Non-Hodgkin Lymphoma Study Group.
    Blood; 2013 Mar 21; 121(12):2253-63. PubMed ID: 23335369
    [Abstract] [Full Text] [Related]

  • 19. Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.
    Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, Maloney DG, Sehn LH, Williams ME, Wilson WH, Leonard JP, Smith SM.
    J Natl Cancer Inst; 2016 Dec 21; 108(12):. PubMed ID: 27986884
    [Abstract] [Full Text] [Related]

  • 20. Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas.
    Pfreundschuh M.
    J Clin Oncol; 2012 Oct 01; 30(28):3433-5. PubMed ID: 22949148
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.